Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free PXMD Stock Alerts

PaxMedica (PXMD) Competitors

PaxMedica logo
$0.0007 0.00 (0.00%)
As of 05/22/2026 01:36 PM Eastern
Compare

PXMD vs. CARM, CMRA, CALA, EFTR, and EVLO

Should you buy PaxMedica stock or one of its competitors? MarketBeat compares PaxMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PaxMedica include Carisma Therapeutics (CARM), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does PaxMedica compare to Carisma Therapeutics?

PaxMedica (NASDAQ:PXMD) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

PaxMedica has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Carisma Therapeutics -254.28%N/A -192.17%

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PaxMedica has higher earnings, but lower revenue than Carisma Therapeutics. PaxMedica is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Carisma Therapeutics Neutral

Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than PaxMedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PaxMedica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Carisma Therapeutics beats PaxMedica on 12 of the 14 factors compared between the two stocks.

How does PaxMedica compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Comera Life Sciences has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
PaxMedica Neutral

4.9% of PaxMedica shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Calithera Biosciences?

PaxMedica (NASDAQ:PXMD) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Calithera Biosciences Neutral

PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

Calithera Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Calithera Biosciences N/A N/A N/A

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Calithera Biosciences beats PaxMedica on 4 of the 7 factors compared between the two stocks.

How does PaxMedica compare to eFFECTOR Therapeutics?

PaxMedica (NASDAQ:PXMD) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

eFFECTOR Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
eFFECTOR Therapeutics N/A N/A N/A

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PaxMedica is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
eFFECTOR Therapeutics Neutral

Summary

eFFECTOR Therapeutics beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
PaxMedica Neutral

Evelo Biosciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

PXMD vs. The Competition

Export
MetricPaxMedicaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.001.4620.9925.66
Price / SalesN/A119.63560.3086.31
Price / CashN/A20.0743.4956.67
Price / Book0.007.5910.417.14
Net Income-$18.29M-$3.64M$3.57B$335.98M
7 Day PerformanceN/A3.01%6.41%4.15%
1 Month PerformanceN/A76.62%3.55%2.54%
1 Year PerformanceN/A126.61%34.12%35.06%

PaxMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXMD
PaxMedica
N/A$0.00
flat		N/A+600.0%$8KN/AN/A2
CARM
Carisma Therapeutics
2.3139 of 5 stars		$0.00
flat		$1.00
+999,900.0%		-99.9%$4K$10.77M0.0020
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
CALA
Calithera Biosciences
N/A$0.00
flat		N/A-66.7%$2KN/AN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A-75.0%$2KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel